UNSPSC 51143211: Lobeline hydrochloride

This classification denotes a nicotinic agonist with the molecular formula C22H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96J834CB88, chemically known as ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, hydrochloride but more generally known as lobeline hydrochloride, which bears US NIH Compound Identifier 46202. European Medicines Agency schedules Lobeline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14389MIG.

Most nations, for tariff and trade purposes, schedule lobeline hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, LOBELINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1[C@@H](CCC[C@@H]1CC(=O)C2CCCCC2)C[C@@H](C3CCCCC3)O.CL.

UNSPSC 51143211 Lobeline hydrochloride is a Commodity code tracking pharmaceutical active ingredients and related drug compounds procured by state and local health agencies. Recent solicitation activity shows minimal direct alignment with the code's nominal scope; the two most recent opportunities posted under this code—Seminole County, Florida's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—involve finished pharmaceutical products, pharmacy benefit management infrastructure, and supply-chain intermediation rather than the raw lobeline hydrochloride chemical itself. This mismatch suggests either broad tagging practices within state procurement systems or that the code is used as a catch-all for pharmaceutical-related acquisitions beyond its strict chemical-ingredient definition.

Issuing bodies posting under this code span county health departments and state health agencies. Seminole County, Florida used an IFB process to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023, while the Texas Health and Human Services Commission issued an RFI (due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. Recent activity centers in Florida and Texas, though the sparse opportunity record and the categorical mismatch between code definition and solicitation content suggest this code warrants close tracking for actual lobeline hydrochloride demand rather than reliance on posted opportunities as a reliable proxy for purchasing intent.